Venus Remedies, an Indian pharmaceutical company, has secured Good Manufacturing Practices (GMP) certification from Ukraine for the production facilities of some of its pharmaceutical products.

These include Meropenem 500mg, Meropenein 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, and Imipenem/Cilastatin 500mg/500mg at their manufacturing unit in Baddi, Himachal Pradesh.

The State Service of Ukraine on Medicine and Drug Control (SMDC) meticulously audited and evaluated Venus Remedies’ operations before granting this prestigious certification. Industry experts anticipate that this achievement will pave the way for GMP certifications from the European Medicines Agency and other regulatory authorities across the globe, including European Union (EU) member states and various countries adhering to the Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S).

As the 27th GMP approval for Venus Remedies, this international recognition holds significant implications for the company’s global expansion plans. With the newfound certification, Venus Remedies is poised to enhance its product portfolio and obtain additional marketing authorizations not only from Ukraine but also from other major pharmaceutical markets worldwide.

Ukraine, boasting a pharmaceutical market worth a staggering $5 billion, ranks among the largest in the Commonwealth of Independent States (CIS) and stands as the second-largest importer of Indian pharmaceutical products after Germany.

Additionally, Venus Remedies’ GMP approval opens doors to the expansive PIC/S network, comprising 54 countries and representing a lucrative market valued at $222 billion. The company has already established a presence in four PIC/S member states and operates in 16 countries within the EU, which offers a massive market potential of $350 billion.

This recent certification further solidifies Venus Remedies’ standing as a global leader in the pharmaceutical industry. The approval encompasses the company’s non-cephalosporin (carbapenem) and oncology parenteral facilities, encompassing liquid and lyophilized injections, ampoules, liquid vials, general lyophilized vials, prefilled syringes, and intravenous fluids.

With GMP certification from Ukraine, Venus Remedies not only expands its reach but also reinforces its commitment to maintaining the highest standards of quality and compliance in pharmaceutical manufacturing. The company is now well-positioned to pursue new avenues of growth and serve patients across various international markets, bringing innovative and life-saving medications to those in need.

Saransh Chaudhary — Venus Remedies President of Global Critical Care said: “This certification is an extended recognition for our manufacturing facilities, which are on a par with international standards in terms of the quality parameters set by Plc/S member nations. This is the 5th time that we have received a PIC/S recognition for our exceptional manufacturing standards, which highlights our unwavering commitment to excellence in pharmaceutical manufacturing and solidifies our position as a leading manufacturer of fixed-do sage injectables.”

  cilastatin, Himachal Pradesh, imipenem, India, Saransh Chaudhary, Ukraine, Venus Remedies